title: Glioblastoma management in the temozolomide era: have we improved outcome?
abstract: Temozolomide (TMZ) during and after radiotherapy (RT) is recommended for patients with newly diagnosed glioblastoma (GBM). We analyzed the adoption of this new standard of care for GBM in an academic cancer centre in Canada and assessed its impact on survival. GBM patients registered with Cancer Care Ontario between 2004 and 2008 were identified. Those ≥ 16 years age, newly diagnosed, treated at our institution, had confirmed pathology and complete records were included. Demographics, treatments, toxicity and outcome were captured. For survival analysis patients were stratified by age, ECOG, and treatment modalities including total cycles of TMZ. Descriptive statistics were used for early progressors and long term survivors. Kaplan-Meier curves, log-rank test and Cox proportional hazards model were used for survival analyses. At a median follow-up of 28 months, we compared our outcome to updated EORTC-NCIC CE 3 results. Of 517 patients 433 were included for analysis. Majority were male (63 %), ECOG 0-1 (66 %), and ≤ 65 years (55 %). 44 % received CRT followed by TMZ, 13 % had CRT only, 30 % had RT only and 13 % had best supportive care. 10 % were early progressors and 9 % survived beyond 2 years. Comparison of our results to NCIC CTG CE.3 study data showed median survival was 15.8 versus 14.6 months, 2 year survival rate for CRT plus TMZ was 35 versus 26 %, and for RT alone 0 versus 10 %, respectively. <50 % of GBM patients complete CRT with TMZ in the real-world setting. Prognosis for most patients with GBM remains dismal particularly if they are not suitable for RT and CRT.
authors: Princess Margaret Hospital, 610 University Avenue, Suite 18-717, Toronto, ON, M5G 2M9, Canada.
authors: Zarnie
authors: Z
authors: Lwin
authors: Derek
authors: D
authors: MacFadden
authors: Ahmed
authors: A
authors: Al-Zahrani
authors: Eshetu
authors: E
authors: Atenafu
authors: Barbara Ann
authors: BA
authors: Miller
authors: Arjun
authors: A
authors: Sahgal
authors: Cynthia
authors: C
authors: Menard
authors: Normand
authors: N
authors: Laperriere
authors: Warren P
authors: WP
authors: Mason
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D059248:Chemoradiotherapy; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019468:Disease Management; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D000077204:Temozolomide; D055815:Young Adult
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide
references: Lancet Oncol. 2006 May;7(5):392-401
references: 16648043
references: JAMA. 2008 Nov 12;300(18):2177-9
references: 19001630
references: Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):100-7
references: 11516858
references: Neurosurgery. 2010 Aug;67(2):446-58
references: 20644432
references: Neuro Oncol. 2012 Sep;14(9):1178-84
references: 22869622
references: J Clin Oncol. 1990 Jul;8(7):1277-80
references: 2358840
references: Lancet Oncol. 2009 May;10(5):459-66
references: 19269895
references: Neurosurgery. 2008 Apr;62(4):753-64; discussion 264-6
references: 18496181
references: Cancer Treat Rev. 2013 Jun;39(4):350-7
references: 22722053
references: Nature. 2012 Feb 15;483(7390):479-83
references: 22343889
references: J Clin Oncol. 2010 Jul 20;28(21):3472-8
references: 20567022
references: J Clin Neurosci. 2012 Nov;19(11):1530-4
references: 22989795
references: Cancer Control. 2003 Mar-Apr;10(2):109-14
references: 12712005
references: N Engl J Med. 2005 Mar 10;352(10):987-96
references: 15758009
references: Lancet Oncol. 2012 Sep;13(9):916-26
references: 22877848
references: N Engl J Med. 2005 Mar 10;352(10):997-1003
references: 15758010
references: Neuro Oncol. 2011 Jan;13(1):84-98
references: 20926426
references: J Clin Epidemiol. 1988;41(5):495-501
references: 3367181
references: Lancet Oncol. 2012 Jul;13(7):707-15
references: 22578793
references: Cancer Cell. 2010 Dec 14;18(6):553-67
references: 21130701
references: N Engl J Med. 2009 Feb 19;360(8):765-73
references: 19228619
references: N Engl J Med. 2009 Jul 23;361(4):328-30
references: 19567829
references: Nature. 2012 Feb 15;483(7390):474-8
references: 22343901
references: Neuro Oncol. 2008 Dec;10(6):1025-34
references: 18667747